University of Nottingham

Cheesecake Energy is developing advanced thermal and compressed air energy systems to store energy from intermittent renewables, turning them into reliable power on-demand.

NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at the University of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham.

One Third Stories makes learning a language as simple as reading a story, one that start in English and end in a different language by utilising their innovative Clockwork Methodology®. These are delivered as part of a monthly subscription box for parents and their kids to embark on a language learning adventure.

NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at the University of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham.

One Third Stories makes learning a language as simple as reading a story, one that start in English and end in a different language by utilising their innovative Clockwork Methodology®. These are delivered as part of a monthly subscription box for parents and their kids to embark on a language learning adventure.

Based in the United Kingdom, Monica Healthcare is developing a series of innovative wearable devices that will use wireless technologies to facilitate globally accessible obstetric services in the home and hospital. The patented technology is based on the acquisition of electro-physiological signals that can be passively detected by electrodes positioned on the maternal abdomen.

Exonate Limited is a biotechnology company focused on the discovery and development of small molecule drugs that target alternative mRNA splicing, specifically in the field of ophthalmology. Founded in 2013 and based in Duxford, United Kingdom, with a research laboratory in Nottingham, Exonate is dedicated to addressing conditions such as diabetic macular oedema (DMO) and wet age-related macular degeneration (wAMD), which are significant causes of vision loss. The company's lead program aims to inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) by selectively targeting the splicing mechanisms mediated by serine/threonine-protein kinase 1 (SRPK1). Exonate has developed a pipeline of small molecule inhibitors that have shown promising efficacy in preclinical models. The company has completed an optimization program supported by the Wellcome Trust, leading to the nomination of a pre-clinical candidate drug. Exonate is guided by an experienced management team with expertise in medicine and drug development, and it aims to apply for regulatory evaluation to advance its therapeutic candidates into clinical trials.

Based in the United Kingdom, Monica Healthcare is developing a series of innovative wearable devices that will use wireless technologies to facilitate globally accessible obstetric services in the home and hospital. The patented technology is based on the acquisition of electro-physiological signals that can be passively detected by electrodes positioned on the maternal abdomen.

Critical Pharmaceuticals Limited is a biotechnology company based in Nottingham, United Kingdom, that specializes in the development of biological drug products using innovative drug delivery technologies. Founded in 2002 by Professor Steve Howdle, the company focuses on non-invasive nasal delivery and sustained release formulations for proteins, peptides, and small molecules. Its proprietary technologies, CriticalSorb and CriticalMix, facilitate the nasal delivery of biologics and the manufacture of depot products that allow for infrequent injections. The company's product pipeline includes CP024, a nasal growth hormone for growth hormone deficiency; CP046, a nasal treatment for osteoporosis; and CP057, a sustained-release formulation of Bevacizumab for age-related macular degeneration, among others. However, as of July 31, 2017, Critical Pharmaceuticals Limited has entered liquidation.